oxybutynin has been researched along with Cancer of Prostate in 8 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antispasmodic effects of the flavone compounds flavoxate hydrochloride, 3-methylflavone carboxylic acid (MFCA), and REC 15/2053 (and in the case of the detrusor, oxybutynin), on the human detrusor, prostatic adenoma, prostatic capsule, and bladder neck, were studied by the in vitro isometric method." | 3.68 | Antispasmodic effects of flavoxate, MFCA, and REC 15/2053 on smooth muscle of human prostate and urinary bladder. ( Caine, M; Gin, S; Pietra, C; Ruffmann, R, 1991) |
| "Men with locally advanced or metastatic prostate cancer were randomly allocated (1:2 from August, 2007 then 1:1 from February, 2011) to either LHRHa according to local practice or tE2 patches (four 100 μg patches per 24 h, changed twice weekly, reducing to three patches twice weekly if castrate at 4 weeks [defined as testosterone ≤1·7 nmol/L])." | 3.01 | Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. ( Alhasso, A; Clarke, NW; Collins, GN; Deighan, JV; Dixit, S; Duong, T; Forcat, S; Gilbert, DC; Kockelbergh, R; Kynaston, H; Langley, RE; Laniado, ME; Macnair, A; Madaan, S; Manetta, C; Mangar, S; Marshall, J; McFarlane, J; Mckay, S; Muazzam, IA; Nankivell, M; Paez, E; Parmar, M; Pope, A; Robinson, A; Rosen, SD; Scrase, CD; Sundaram, SK; Weiss, M; Williams, ST; Worlding, J, 2021) |
| "Men with locally advanced or metastatic prostate cancer participating in an ongoing randomised, multicentre UK trial comparing tE2 versus LHRHa for ADT were enrolled into a QoL sub-study." | 2.84 | Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. ( Abel, PD; Alhasso, AA; Cafferty, FH; Collins, G; Dixit, S; Duong, T; Gilbert, DC; Kanaga-Sundaram, S; Kynaston, HG; Langley, RE; Laniado, M; Madaan, S; Nankivell, M; Parmar, MK; Pope, A; Rosen, SD; Wassersug, R; Welland, A, 2017) |
| "This study found that prostate cancer patients treated with transdermal oestradiol for hormonal therapy did not experience the loss in bone mineral density seen with luteinising hormone-releasing hormone agonists." | 2.82 | A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol. ( Abel, PD; Abel, RL; Alhasso, AA; Cafferty, F; Carpenter, R; Duong, T; Honeyfield, L; Jovic, G; Kynaston, HG; Langley, RE; Paez, EM; Parmar, MK; Robertson, A; Scrase, CD; Stone, M; Welland, A, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Smith, TJ | 1 |
| Loprinzi, CL | 1 |
| Deville, C | 1 |
| Callier, C | 1 |
| Tauzin-Fin, P | 1 |
| Bram, R | 1 |
| Ballanger, P | 1 |
| Kelly, PM | 1 |
| Baxter, GM | 1 |
| Caine, M | 1 |
| Gin, S | 1 |
| Pietra, C | 1 |
| Ruffmann, R | 1 |
| Langley, RE | 3 |
| Gilbert, DC | 3 |
| Duong, T | 4 |
| Clarke, NW | 1 |
| Nankivell, M | 2 |
| Rosen, SD | 2 |
| Mangar, S | 1 |
| Macnair, A | 1 |
| Sundaram, SK | 1 |
| Laniado, ME | 1 |
| Dixit, S | 2 |
| Madaan, S | 2 |
| Manetta, C | 1 |
| Pope, A | 2 |
| Scrase, CD | 2 |
| Mckay, S | 1 |
| Muazzam, IA | 1 |
| Collins, GN | 1 |
| Worlding, J | 1 |
| Williams, ST | 1 |
| Paez, E | 1 |
| Robinson, A | 1 |
| McFarlane, J | 1 |
| Deighan, JV | 1 |
| Marshall, J | 1 |
| Forcat, S | 1 |
| Weiss, M | 1 |
| Kockelbergh, R | 1 |
| Alhasso, A | 1 |
| Kynaston, H | 1 |
| Parmar, M | 2 |
| Sydes, M | 1 |
| Bara, A | 1 |
| Clarke, N | 1 |
| Abel, P | 1 |
| James, N | 1 |
| Langley, R | 1 |
| Kynaston, HG | 2 |
| Alhasso, AA | 2 |
| Paez, EM | 1 |
| Jovic, G | 1 |
| Robertson, A | 1 |
| Cafferty, F | 1 |
| Welland, A | 2 |
| Carpenter, R | 1 |
| Honeyfield, L | 1 |
| Abel, RL | 1 |
| Stone, M | 1 |
| Parmar, MK | 2 |
| Abel, PD | 2 |
| Cafferty, FH | 1 |
| Kanaga-Sundaram, S | 1 |
| Laniado, M | 1 |
| Collins, G | 1 |
| Wassersug, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized-Controlled Trial of Transcutaneous Oestrogen Patches Versus LHRH Agonists in Prostate Cancer[NCT00303784] | Phase 3 | 2,200 participants (Anticipated) | Interventional | 2006-03-31 | Recruiting | ||
| STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial[NCT00268476] | Phase 2/Phase 3 | 11,992 participants (Actual) | Interventional | 2005-07-08 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for oxybutynin and Cancer of Prostate
| Article | Year |
|---|---|
[Effect of sublingual oxybutynin in postoperative pain after radical retropubic prostatectomy].
Topics: Adenocarcinoma; Administration, Sublingual; Aged; Humans; Male; Mandelic Acids; Middle Aged; Muscari | 2009 |
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
Topics: Acute Coronary Syndrome; Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Embolic Stro | 2021 |
Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform.
Topics: Administration, Cutaneous; Androgen Antagonists; Estradiol; Humans; Male; Prostatic Neoplasms; Trans | 2018 |
Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform.
Topics: Administration, Cutaneous; Androgen Antagonists; Estradiol; Humans; Male; Prostatic Neoplasms; Trans | 2018 |
Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform.
Topics: Administration, Cutaneous; Androgen Antagonists; Estradiol; Humans; Male; Prostatic Neoplasms; Trans | 2018 |
Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform.
Topics: Administration, Cutaneous; Androgen Antagonists; Estradiol; Humans; Male; Prostatic Neoplasms; Trans | 2018 |
A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.
Topics: Absorptiometry, Photon; Adenocarcinoma; Administration, Cutaneous; Aged; Aged, 80 and over; Androgen | 2016 |
Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.
Topics: Adenocarcinoma; Administration, Cutaneous; Aged; Aged, 80 and over; Androgen Antagonists; Estradiol; | 2017 |
3 other studies available for oxybutynin and Cancer of Prostate
| Article | Year |
|---|---|
Oxybutynin for Hot Flashes Due to Androgen Deprivation in Men.
Topics: Aged; Androgen Antagonists; Anilides; Hot Flashes; Humans; Leuprolide; Male; Mandelic Acids; Muscari | 2018 |
Solitary fibrous tumour of the prostate.
Topics: Humans; Male; Mandelic Acids; Mesothelioma; Middle Aged; Muscarinic Antagonists; Prostatic Neoplasms | 1998 |
Antispasmodic effects of flavoxate, MFCA, and REC 15/2053 on smooth muscle of human prostate and urinary bladder.
Topics: Adenoma; Dose-Response Relationship, Drug; Flavoxate; Humans; Male; Mandelic Acids; Muscle Contracti | 1991 |